Abstract
Objectives: This study aims to analyze the of drug costs for patients with chronic diseases in the capitation system in public primary health cares (Public PHCs).
 Materials and Methods: This research is a quantitative study with an observational cross-sectional approach at 16 Public PHCs. Data collection used the retrospective method. The total sample was 293 outpatients in 2016.
 Results: The results showed that 63% of patients are female. The most patients are aged between 56-65 years (37%). The average drug cost for patients receiving more than 3 types of drugs is IDR 7,726. The biggest drug cost is patients with DM type 2 with which the average cost is IDR 7.400. And the metformin treatment is 17 (6%) patients with the cost IDR 4,500,-. Chi-square analysis shows that the quantity of drug items, type of disease and prescriptions there are have significant effect on drug cost (p-value <0.05). However, gender and age group there are no significant effect on drug cost (p-value >0.05). Drug prescriptions are an important component in managing chronic diseases patients. Prescribing costs provide important information in the sustainability of the management of chronic disease programs.
 Conclusion: This study recommends that the prolanis policy in public PHCs is focused on the elderly age group patients and female group.
 Bangladesh Journal of Medical Science Vol.20(4) 2021 p.762-767
Highlights
WHO data showed that chronicle disease claims the lives of more than 35 million people, including young and middle-aged people 1
This study aims to analyze the utilization of drug costs for patients with chronic diseases in the capitation system in Public PHCs
The relationship of drug cost based on patients, age group of Diabetes Mellitus and Hypertension
Summary
WHO data showed that chronicle disease claims the lives of more than 35 million people, including young and middle-aged people 1. Chronic diseases treatment becomes a global problem for health care providers. It is hoped that the patients adhere to treatment since it closely deals with health financial sources 2, 3,4. Patients with hypertension and type 2 diabetes mellitus in the world are increasing every year; it is estimated that by 2025 there will be 1.5 billion people suffering from hypertension. Diabetes mellitus (DM) type 2 is included in the ten non-communicable diseases, which placed at the highest ranks with the most cases happened, and it raises the highest financial costs. It is estimated that every year, there are 9.4 million people die from hypertension, and 4;5. DM type 2 places a substantial economic burden on patients and the health care system 6. In the US, the costs of pre-diabetes and diabetes have increased from $ 174 billion to $ 245 billion in 2012, including direct medical costs of $ 176 billion and $ 69 billion indirect costs due to severe disability and loss of productivity 7, 8
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call